Investment: Problems under the surface at Zeneca
Friday 07 August 1998
It has a decent drugs portfolio - its asthma treatment Accolate is still the star performer - backed up by a pipeline with a couple of potential best-sellers. The agrochemicals division, which has been a drag on earnings for some time, is set to benefit from recent restructuring, with fungicides already delivering growth.
Add a problem-free balance sheet and you can see why the market believes Zeneca is strong enough to keep its promise of growing underlying earnings by 15 per cent a year.
Yesterday's first-half results, which showed a 2 per cent slide in profits to pounds 654m after a heavy hit from sterling, Asia and the millennium bug, did little to dent this belief. The shares firmed 15p to 2280p after a pretty poor run in the weeks leading up to the figures.
So can Zeneca be discharged with a clean bill of health? Not really. If investors scratch the surface, they will see that some of the star drugs - including two blockbusters, the hypertension treatment Zestril and the cancer drug Novaldex - are set to lose patent protection in 2002. The new compounds which were supposed to replace them, notably the schizophrenia drug Seroquel, have got off to a slow start while the mature ones will suffer from increased competition.
At the same time, the agrochemicals division will be hit by difficult market conditions and shrinking margins. True, Zeneca could be taken over by one of the pharmaceutical giants, but no credible suitor willing to pay a premium has materialised despite years of speculation. And with the shares trading at almost 30 times expected 1998 earnings of around pounds 1.1bn - a 60 per cent premium to the market - the prescription is: sell into strength.
- 1 Enrique Iglesias injured trying to catch a drone mid concert
- 2 Caitlyn Jenner, formerly Bruce Jenner, reveals new look on Annie Leibovitz shot Vanity Fair cover
- 4 Man on naked bike ride gets ejected after becoming aroused
Migrants in Kos: Photos show real tragedy after Brits abroad complain of 'awkward' holidays
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
Michael Gove determined to scrap the Human Rights Act – even if Scotland retains it
Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination
Threat to scrap Human Rights Act could see UK follow Nazi example, warns UN official
Why this year's general election was the most unfair in Britain's history
iJobs Money & Business
£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...
£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...
£25 - £30K: Guru Careers: We are seeking a highly-motivated and ambitious Comm...
£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...